Rachel Vatnsdal
Stock Analyst at JP Morgan
(4.04)
# 452
Out of 4,829 analysts
63
Total ratings
51.16%
Success rate
12.58%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $8.77 | +2.62% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $30.82 | +7.07% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $123.20 | +54.23% | 6 | Apr 29, 2025 | |
| RVTY Revvity | Maintains: Neutral | $120 → $100 | $91.25 | +9.59% | 4 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $17.59 | +8.02% | 4 | Mar 6, 2025 | |
| WAT Waters | Maintains: Neutral | $380 → $390 | $344.06 | +13.35% | 4 | Mar 6, 2025 | |
| TEM Tempus AI | Downgrades: Neutral | $50 → $55 | $61.37 | -10.38% | 3 | Feb 25, 2025 | |
| GH Guardant Health | Maintains: Overweight | $50 → $55 | $41.72 | +31.83% | 1 | Feb 21, 2025 | |
| A Agilent Technologies | Maintains: Overweight | $165 → $160 | $106.93 | +49.63% | 6 | Nov 26, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $650 → $670 | $403.13 | +66.20% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $88 → $80 | $68.64 | +16.55% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $3.89 | +414.14% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.10 | - | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,080.98 | +29.51% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $6 | $9.03 | -33.55% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.12 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $37.52 | +139.87% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $189.73 | +42.31% | 4 | Dec 20, 2023 |
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $8.77
Upside: +2.62%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $30.82
Upside: +7.07%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $123.20
Upside: +54.23%
Revvity
Apr 29, 2025
Maintains: Neutral
Price Target: $120 → $100
Current: $91.25
Upside: +9.59%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $17.59
Upside: +8.02%
Waters
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $344.06
Upside: +13.35%
Tempus AI
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $61.37
Upside: -10.38%
Guardant Health
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $41.72
Upside: +31.83%
Agilent Technologies
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $106.93
Upside: +49.63%
Thermo Fisher Scientific
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $403.13
Upside: +66.20%
Aug 12, 2024
Maintains: Overweight
Price Target: $88 → $80
Current: $68.64
Upside: +16.55%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $3.89
Upside: +414.14%
Aug 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.10
Upside: -
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,080.98
Upside: +29.51%
Aug 2, 2024
Maintains: Overweight
Price Target: $5 → $6
Current: $9.03
Upside: -33.55%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.12
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $37.52
Upside: +139.87%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $189.73
Upside: +42.31%